HEALTH PROFESSIONAL · SOURCE READING

Durvalumab

Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 2, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Stage IV Bladder Cancer / Treatment Options for Stage IV Bladder Cancer / Treatment options for patients with any T, any N, M1 disease / Immunotherapy

Durvalumab is an anti–PD-L1 monoclonal antibody with activity when given perioperatively with neoadjuvant chemotherapy in patients with resectable disease. However, durvalumab was voluntarily withdrawn in 2021 as a first-line therapy for locally advanced or metastatic urothelial cancer. The withdrawal was based on the randomized DANUBE trial (NCT02516241) which showed no significant improvement in OS.[65][Level of evidence A1]

Source links and citations

Studies cited in this source section

Source citation is not a determination that a study applies to you.

NCT02516241 · design, results and side effects

Publication references

Read the original reference and check its publication notices.

PubMed 32971005 · Original source

Preserved source evidence · Not medical advice